JP2014502961A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502961A5
JP2014502961A5 JP2013543601A JP2013543601A JP2014502961A5 JP 2014502961 A5 JP2014502961 A5 JP 2014502961A5 JP 2013543601 A JP2013543601 A JP 2013543601A JP 2013543601 A JP2013543601 A JP 2013543601A JP 2014502961 A5 JP2014502961 A5 JP 2014502961A5
Authority
JP
Japan
Prior art keywords
seq
composition
peptide
peptides
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013543601A
Other languages
English (en)
Japanese (ja)
Other versions
JP6032853B2 (ja
JP2014502961A (ja
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/en
Application filed filed Critical
Priority claimed from PCT/EP2011/070024 external-priority patent/WO2012079878A2/en
Publication of JP2014502961A publication Critical patent/JP2014502961A/ja
Publication of JP2014502961A5 publication Critical patent/JP2014502961A5/ja
Application granted granted Critical
Publication of JP6032853B2 publication Critical patent/JP6032853B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013543601A 2010-12-14 2011-11-14 前立腺関連抗原分子由来hla結合ペプチドおよびその使用方法 Expired - Fee Related JP6032853B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/069675 WO2011073215A2 (en) 2009-12-14 2010-12-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EPPCT/EP2010/069675 2010-12-14
PCT/EP2011/070024 WO2012079878A2 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2014502961A JP2014502961A (ja) 2014-02-06
JP2014502961A5 true JP2014502961A5 (https=) 2014-12-25
JP6032853B2 JP6032853B2 (ja) 2016-11-30

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543601A Expired - Fee Related JP6032853B2 (ja) 2010-12-14 2011-11-14 前立腺関連抗原分子由来hla結合ペプチドおよびその使用方法

Country Status (9)

Country Link
JP (1) JP6032853B2 (https=)
KR (1) KR20130126671A (https=)
CN (1) CN103547283A (https=)
AU (1) AU2011344652B2 (https=)
CA (1) CA2821582A1 (https=)
MX (1) MX2013006758A (https=)
NZ (1) NZ609916A (https=)
SG (1) SG191154A1 (https=)
WO (1) WO2012079878A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
US11058768B2 (en) * 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
EP4286511A3 (en) * 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
US11965892B2 (en) * 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2003521245A (ja) * 1999-12-21 2003-07-15 エピミューン, インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003217421A1 (en) * 2002-02-19 2003-09-09 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004053075A2 (en) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
EP1642905B1 (en) 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
ES2532896T5 (es) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera

Similar Documents

Publication Publication Date Title
JP2014502961A5 (https=)
AR121588A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2020001897A1 (es) Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
JP2018509935A5 (https=)
MX377144B (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
JP2018510215A5 (https=)
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
CA3033115A1 (en) Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины
EP2528937A4 (en) MODIFIED MELK-PEPTIDES AND VACCINES CONTAINING THEREOF
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
MX2020011787A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
MY170949A (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
NZ593200A (en) Peptide adjuvants
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos